Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
| Condition(s) | NSCLC Stage IV, Brain Metastases, Adult |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy. |
| Who can participate | Inclusion Criteria: * In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Signed informed consent must be obtained prior to participation in the study. 2. Participant is an adult ≥ 18 years of age at the time of informed consent. 3. ECOG performance status ≤1. 4. Estimated life expectancy of 12 weeks or more. 5. Pathology proven metastatic non-squamous NSCLC 6. For those without an actionable oncogenic driver: progression on immunotherapy and/or platinum-doublet chemotherapy (concurrent or sequential, in any order). If contra-indication for immunotherapy: progression on platinum-doublet chemotherapy. 7. For those with an actionable oncogenic driver: progression on targeted therapy and platinum-doublet chemotherapy. For the latter grou |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Maastricht University Medical Center |
| Locations | Amsterdam, Netherlands; Groningen, Netherlands; Maastricht, Netherlands |
| Start date | 2025-04-24 |
| NCT ID | NCT06401824 |
| Official listing | https://clinicaltrials.gov/study/NCT06401824 |